Investigational Gene Therapy for Adults with CF Request More Information Trial Objective This study is designed to test the safety of 4D-710, an investigational gene therapy drug for adults with cystic fibrosis (CF) who are unable to use CFTR modulators. Adeno-associated viruses (AAV) are small viruses that are commonly found in nature and are not known to cause disease in humans. 4D-710 is an AAV that was changed in the laboratory to deliver a copy of the CFTR gene to the lungs, thereby providing a copy of instructions for making normal CFTR protein. Participants will use a nebulizer to inhale 4D-710 into the lungs to see if 4D-710 is safe for use in adults with cystic fibrosis and to see if 4D-710 can help lung function. Enrollment Active Clinical Trials Currently Recruiting Who Can Participate Adults with CF who are not eligible for CFTR modulatory therapy or discontinued CFTR modulator therapy due to side effects. Age: 18+ Gender: Any Gender Estimated Time Commitment 24 months Year 1: 10 scheduled in-person visits. Year 2: Long-term follow up, phone check in. × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Provided Travel Reimbursement: Available Trial Contact For more information, contact: Samantha Johnson 303.270.2598 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors 4D Molecular Therapeutics, Inc. Principal Investigators Jennifer Taylor-Cousar, MD, MSCS + × Jennifer Taylor-Cousar, MD, MSCS Medical Director, Clinical Research Services Co-Director, Adult Cystic Fibrosis Program Director, Cystic Fibrosis Therapeutics Development Center Adult Program Professor Division of Pulmonary, Critical Care & Sleep Medicine Department of Medicine Division of Pediatric Pulmonary Medicine Department of Pediatrics President, Medical Staff View Full Profile Patient Rating 4.8 out of 5 stars Make an Appoinment Co-Investigators Jane Gross, MD, PhD + × Jane Gross, MD, PhD Assistant Professor Division of Pediatric Pulmonary Medicine Department of Pediatrics View Full Profile Make an Appoinment Jerry Nick, MD + × Jerry Nick, MD Professor Director, Adult Cystic Fibrosis Program Rebecca Runyon Bryan Chair in Cystic Fibrosis Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine View Full Profile Patient Rating 4.8 out of 5 stars Make an Appoinment Request More Information By completing this form, you agree to learn more about this study and see if you qualify. First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective This study is designed to test the safety of 4D-710, an investigational gene therapy drug for adults with cystic fibrosis (CF) who are unable to use CFTR modulators. Adeno-associated viruses (AAV) are small viruses that are commonly found in nature and are not known to cause disease in humans. 4D-710 is an AAV that was changed in the laboratory to deliver a copy of the CFTR gene to the lungs, thereby providing a copy of instructions for making normal CFTR protein. Participants will use a nebulizer to inhale 4D-710 into the lungs to see if 4D-710 is safe for use in adults with cystic fibrosis and to see if 4D-710 can help lung function.